• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

    4.640 +0.050 (+1.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 348,359
    Open 4.580
    Bid (Size) 4.500 (1)
    Ask (Size) 4.640 (3)
    Prev. Close 4.590
    Today's Range 4.400 - 4.750
    52wk Range 2.470 - 9.240
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
    Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support... 
    Via Benzinga
    Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +33.72%
    +33.72%
    1 Month
    +24.73%
    +24.73%
    3 Month
    +79.84%
    +79.84%
    6 Month
    +52.63%
    +52.63%
    1 Year
    -39.03%
    -39.03%

    More News

    Read More
    Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience: Q4 Earnings Insights
    Via Benzinga
    Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
    Via InvestorPlace
    Why Is Branchout Food (BOF) Stock Down 39% Today?
    Via InvestorPlace
    Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
    Via InvestorPlace
    3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
    Via InvestorPlace
    Vigil Neuroscience to Present in Upcoming June Investor Conferences
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
    Via InvestorPlace
    Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
    Via InvestorPlace
    Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.